GNI invests into artificial intelligence technology assisted diagnosis

January 17, 2019 – GNI Group Ltd., a fast-growing pharmaceutical company, today announced an investment into Reveal Biosciences, Inc., a computational pathology diagnosis company in San Diego, California. The goal of this investment is to develop new means to improve the accuracy of diagnosis of liver fibrosis and lung fibrosis through employing artificial intelligence and other data mining tools. After this investment, GNI Group's U.S. subsidiary, GNI USA, Inc., will own 6% of Reveal Biosciences. Other investors in the Series A round include Intel Capital. This investment will not have material impact on GNI's financial performance in 2019.

Accurate diagnosis has always been a major challenge in treating liver and lung fibrosis patients. Traditionally, medical imaging is critical in such diagnosis, depending on the assessment of experienced doctors in the field. However, time requirements and inconsistency in the diagnosis process can hamper the clinical development and commercialization of key drug candidates. Inability to accurately diagnose patients with liver and lung fibrosis can delay or prevent patients from receiving timely and effective treatment. GNI Group has been seeking new technologies, especially artificial intelligence, to employ in the pathological field to realize faster and more accurate diagnosis results.

Reveal Biosciences has been engaged in the development and commercialization of histopathology diagnostic tools since its startup in 2012. The company has successfully partnered with other service providers in America to deliver accurate and reproducible results on a larger scale for precision medicine. The successful commercialization of Reveal's technology enabled Reveal to be consistently profitable. Reveal Biosciences and GNI Group will work together to expand the AI diagnosis business in Asia to benefit fibrosis patients. Further information about Reveal Biosciences can be found at www.revealbio.com.

About GNI Group Ltd.
GNI Group Ltd. is a multinational pharmaceutical company listed on the Tokyo Stock Exchange Mothers Market, Code 2160. The Group is headquartered in Tokyo, with primary business units of pharmaceuticals and medical devices with subsidiaries in Hong Kong, Shanghai, Beijing and the United States. For further information about GNI Group Ltd., please visit www.gnipharma.com.

For further inquiries
Email: infojapan@gnipharma.com